原发性胆汁性胆管炎的药物治疗进展

雷柳洁; 唐映梅

doi:10.3969/j.issn.1001-5256.2017.06.037

原发性胆汁性胆管炎的药物治疗进展

DOI: 10.3969/j.issn.1001-5256.2017.06.037

昆明医科大学第二附属医院消化内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 1714
- HTML全文浏览量: 18
- PDF下载量: 434
- 被引次数: 0
出版历程
- 收稿日期: 2017-02-27
- 出版日期: 2017-06-20

Advances in pharmacotherapy for primary biliary cholangitis

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

摘要

摘要: 原发性胆汁性胆管炎（PBC）的发病机制尚不完全清楚,熊去氧胆酸是目前唯一被美国食品药品监督管理局批准的治疗药物,但部分患者对其应答不良,亟需探索新的治疗方法。综述了PBC的药物进展情况,包括6-α乙基鹅去氧胆酸、贝特类、布地奈德、生物制剂等药物,指出这些药物为PBC患者带来新希望,但仍需大型临床研究证实其长期疗效及安全性。
- 肝硬化,胆汁性 /
- 治疗 /
- 综述
Abstract: The pathogenesis of primary biliary cholangitis (PBC) remains unclear. Ursodeoxycholic acid (UDCA) is currently the only drug approved by the Food and Drug Administration for the treatment of PBC, but some patients have a poor response to UDCA. New therapies can be considered for these patients. This article reviews the advances in drugs for PBC, including 6α-ethyl-chenodeoxycholic acid, fibrates, budesonide, and biological agents, and points out that these drugs bring new hope for PBC patients, but large-scale clinical studies are needed to confirm the long-term efficacy and safety.
- liver cirrhosis, biliary /
- therapy /
- review

HTML全文

参考文献(40)

[1]BOONSTRA K, BEUERS U, PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol, 2012, 56 (5) :1181-1188.

[2]CARBONE M, LLEO A, SANDFORD RN, et al.Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis[J].Eur J Immunol, 2014, 44 (4) :945-954.

[3]TABIBIAN JH, LINDOR KD.Primary biliary cirrhosis:safety and benefits of established and emerging therapies[J].Expert Opin Drug Saf, 2015, 14 (9) :1435-1444.

[4]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1) :s3-s12.

[5]RUDIC JS, POROPAT G, KRSTIC MN, et al.Ursodeoxycholic acid for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2012, 12:cd000551.

[6]GONG Y, HUANG Z, CHRISTENSEN E, et al.Ursodeoxycholic acid for patients with primary biliary cirrhosis:an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses[J].Am J Gastroenterol, 2007, 102 (8) :1799-1807.

[7]ZHANG LL, FAN YJ, TAN B, et al.Recognition of the clinical application and biological mechanism of ursodeoxycholic acid in liver diseases[J].Chin J Clin Pharmacol Ther, 2017, 22 (2) :233-240. (in Chinese) 张林林, 樊玉娟, 谭波, 等.熊脱氧胆酸在慢性肝病中应用及机制的再认识[J].中国临床药理学与治疗学, 2017, 22 (2) :233-240.

[8]CARBONE M, MELLS GF, PELLS G, et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J].Gastroenterology, 2013, 144 (3) :560-569.

[9]GUO GY, SHI YQ, WANG L, et al.Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis[J].Aliment Pharmacol Ther, 2015, 42 (2) :221-230.

[10]LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology, 2014, 147 (6) :1338-1349.

[11]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.

[12]HIRSCHFIELD G, KOWDLEY K, MASON A.Long-term (LT) therapy of a farnesoid X receptor (FXR) agonist obeticholic acid (OCA) maintains biochemical response in primary biliray cirrhosis (PBC) [J].J Hepatol, 2012, 56:s372.

[13]KOWDLEY KV, JONES D, LUKETIC V, et al.An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC[J].J Hepatol, 2011, 54:s13.

[14]YU Y, YANG ZG, CHEN SS, et al.Efficacy of adjuvant therapy with fenofibrate for primary biliary cirrhosis:a meta—analysis[J].J Clin Hepatol, 2015, 31 (10) :1630-1633. (in Chinese) 俞媛, 杨宗国, 陈姼姼, 等.非诺贝特辅助治疗原发性胆汁性肝硬化效果的Meta分析[J].临床肝胆病杂志, 2015, 31 (10) :1630-1633.

[15]LENS S, LEOZ M, NAZAL L, et al.Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid[J].Liver Int, 2014, 34 (2) :197

[16]DOHMEN K, TANAKA H, HARUNO M.The effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis[J].Fukuoka Acta Med, 2013, 104 (10) :350-361.

[17]LEVY C, PETER JA, NELSON DR, et al.Pilot study:fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Aliment Pharmacol Ther, 2011, 33 (2) :235-242.

[18]HAN XF, WANG QX, LIU Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis, 2012, 13 (4) :219-224.

[19]OHIRA H, SATO Y, UENO T, et al.Fenofibrate treatment in patients with primary biliary cirrhosis[J].Am J Gastroenterol, 2002, 97 (8) :2147-2149.

[20]ZHANG Y, LI S, HE L, et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a metaanalysis[J].Drug Des Devel Ther, 2015, 9:2757-2766.

[21]CORPECHOT C.Primary biliary cirrhosis beyond ursodeoxycholic acid[J].Semin Liver Dis, 2016, 36 (1) :15-26.

[22]HOSONUMA K, SATO K, YAMAZAKI Y, et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol, 2015, 110 (3) :423-431.

[23]YIN Q, LI J, XIA Y, et al.Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis[J].Drug Des Devel Ther, 2015, 9:5407-5419.

[24]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.

[25]RABAHI N, CHRETIEN Y, GAOUAR F, et al.Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol, 2010, 34 (4-5) :283-287.

[26]LOVETT-RACKE AE, HUSSAIN RZ, NORTHROP S, et al.Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease[J].J Immunol, 2004, 172 (9) :5790-5798.

[27]HEMPFLING W, GRUNHAGE F, DILGER K, et al.Pharmacokinetics and pharmacodynamic action of budesonide in earlyand latestage primary biliary cirrhosis[J].Hepatology, 2003, 38 (1) :196-202.

[28]SILVEIRA MG, LINDOR KD.Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis[J].Expert Opin Pharmacother, 2014, 15 (3) :365-372.

[29]European Association for the Study of the L.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].J Hepatol, 2009, 51 (2) :237-267.

[30]WANG L, LI J, LIU H, et al.Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis[J].J Gastroenterol Hepatol, 2013, 28 (Suppl 1) :85-92.

[31]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Phase 2study evaluating the efficacy and safety of ustekunumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid[J].J Hepatol, 2014, 60 (1) :s189-s190.

[32]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.

[33]MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.

[34]MASON AL, FARR GH, XU L, et al.Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis[J].Am J Gastroenterol, 2004, 99 (12) :2348-2355.

[35]MASON AL, LINDOR KD, BACON BR, et al.Clinical trial:randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol[J].Aliment Pharmacol Ther, 2008, 28 (7) :886-894.

[36]GONG Y, CHRISTENSEN E, GLUUD C.Azathioprine for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2007, (3) :cd006000.

[37]LIE TS, PREISSINGER H.Successful treatment of primary biliary cirrhosis with cyclosporin[J].Dtsch Med Wochenschr, 1990, 115 (18) :698-702.

[38]GILJACA V, POROPAT G, STIMAC D, et al.Methotrexate for primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2010, (5) :cd004385.

[39]TREIBER G, MALFERTHEINER P.Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J].J Clin Gastroenterol, 2005, 39 (9) :837-838.

[40]ZHU GQ, SHI KQ, HUANG S, et al.Network meta-analysis of randomized controlled trials:efficacy and safety of UDCA-based therapies in primary biliary cirrhosis[J].Medicine (Baltimore) , 2015, 94 (11) :e609.

施引文献

资源附件(0)

访问统计